- Exicure, Inc. (XCUR, Financial) has received a Nasdaq non-compliance notice for a late Form 10-Q filing.
- The company has 60 days to submit a compliance plan; could extend compliance deadline to November 17, 2025.
- Exicure is making efforts to file the overdue report promptly and regain compliance.
Exicure, Inc. (XCUR), a clinical-stage biotechnology firm, announced that it received a notice of non-compliance from Nasdaq Stock Market LLC due to its failure to timely file its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025. The Nasdaq notice highlights a violation of Listing Rule 5250(c)(1), which mandates timely filing of all periodic financial reports with the U.S. Securities and Exchange Commission (SEC).
According to Nasdaq's listing requirements, Exicure now has 60 calendar days to submit a plan to rectify this issue. If Nasdaq accepts the proposed plan, Exicure could be granted an extension of up to 180 calendar days from the original due date of May 20, 2025, which would be until November 17, 2025, to regain compliance.
The company has stated that it is diligently working on completing the required Form 10-Q and intends to file it as soon as possible to comply with Nasdaq regulations.
Exicure focuses on developing therapies to tackle challenges in hematologic diseases, with its primary program, GPC-100, under evaluation for stem cell mobilization benefits in multiple myeloma and sickle cell disease, and as a potential chemosensitizing agent in acute myeloid leukemia (AML).
